FDA expands access to BioVentrix ischemic heart failure treatment

BioVentrix announced today that it received FDA approval for its application for an expanded access program for the Revivent TC system.

San Ramon, California-based BioVentrix designed the Revivent TC system to support a minimally invasive heart procedure. It treats a dilated left ventricle of patients with ischemic heart failure. They also have reduced ejection fraction and extensive left ventricular scar. These patients have a suboptimal response to guideline-directed medical therapy.

The procedure — called less invasive ventricular enhancement (LIVE) therapy — uses myocardial micro-anchor implants. These implants help to reconstruct the dilated left ventricle, producing a more efficient chamber.

Approval follows the successful completion of enrollment in the ALIVE trial. The prospective, multi-center, dual-arm pivotal study evaluating the Revivent TC system completed enrollment in April 2022.

Gregg Stone, co-principal investigator, said the expa…

Read more
  • 0

BioVentrix expands heart failure treatment portfolio with MateraCor acquisition

BioVentrix announced today that it has acquired MateraCor, a company developing injectable alginate-based hydrogel to treat heart failure.

San Ramon, Calif.–based BioVentrix is a privately held medical device company focused on less invasive therapies to treat the left ventricle.

The financial terms of the deal were not disclosed.

“This is an exciting time for BioVentrix as we build a platform of synergistic therapies to treat a dilated left ventricle, the root cause of ischemic and idiopathic heart failure,” BioVentrix CEO Jim Dillon said in a news release.

Dillon added that buying MateraCor and its lead Trans-Catheter Myocardial Restoration (TCMR) product reinforces BioVentrix’s position to treat left ventricular heart failure with a variety of products and services.

Also today, BioVentrix announced the appointment of Steve Chartier, former VP of global clinical affairs at liver cancer therapies company Sirtex Medical, as the compan…

Read more
  • 0

BioVentrix appoints Jim Dillion president and CEO

BioVentrix today said it appointed Jim Dillion as president and CEO.

Prior to joining the company, Dillion was the cofounder of Reprieve Cardiovascular and led its financing and development of a therapy for acute decompensated heart failure. He has also held a number of leadership roles at St. Jude Medical, Abiomed, TherOx and InfraReDx.

“Jim’s field-based leadership style, combined with his proven success in building high-performance global teams, makes him the ideal candidate to lead our company,” board chairperson Steven Healy said in a news release. “Jim’s knowledge and experience in market development, ability to ensure a business’s financial integrity and his strong relationships with renowned physicians will prove highly beneficial in building BioVentrix and optimizing shareholder value. I would also like to thank Ken Miller for his years of service and many contributions to BioVentrix.”

“I am excited to join the BioVentrix team at a pivotal time …

Read more
  • 0